Breast最新文献

{"title":"Eligibility for bilateral prophylactic mastectomy: An expert opinion study in the Netherlands","authors":"L.P. Jansen , G.M. Kramer , E.G. Engelhardt , C.W. van der Zee , I. van de Beek , M.A. Adank , M.T.F.D. Vrancken Peeters , M.K. Schmidt , C.A. Drukker","doi":"10.1016/j.breast.2025.104645","DOIUrl":"10.1016/j.breast.2025.104645","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104645"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145569972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer","authors":"Amandine Billaud ,&nbsp;Gisella Figlioli ,&nbsp;Clémence Mooser ,&nbsp;Irene Casamassima ,&nbsp;Violette Azzoni ,&nbsp;Jahnavi Srivatsa ,&nbsp;Mara Colombo ,&nbsp;Laura Caleca ,&nbsp;Thomas U. Ahearn ,&nbsp;Irene L. Andrulis ,&nbsp;Antonis C. Antoniou ,&nbsp;Matthias W. Beckmann ,&nbsp;Sabine Behrens ,&nbsp;Marina Bermisheva ,&nbsp;Natalia V. Bogdanova ,&nbsp;Manjeet K. Bolla ,&nbsp;Bernardo Bonanni ,&nbsp;Thomas Brüning ,&nbsp;Nicola J. Camp ,&nbsp;Archie Campbell ,&nbsp;Paolo Peterlongo","doi":"10.1016/j.breast.2025.104619","DOIUrl":"10.1016/j.breast.2025.104619","url":null,"abstract":"<div><div>The breast cancer risk conferred by germline protein truncating variants (PTVs) in known and putative breast cancer genes has been extensively investigated. However, the effect of <em>FANCM</em> PTVs on breast cancer risk remains unclear. Our previous clinical, genetic and functional results on the N-terminal p.Arg658∗ and the two C-terminal p.Gln1701∗ and p.Gly1906Alafs∗12 variants suggested that <em>FANCM</em> PTVs may confer different risks for ER-negative (ER-neg) and triple-negative (TN) breast cancer subtypes.</div><div>Here, we performed meta-analyses of seven studies totaling 144 681 breast cancer cases and 123 632 controls. <em>FANCM</em> PTVs were tested for association with breast cancer risk overall and the disease clinical subtypes by single variant and burden analyses. Two CRISPR-Cas9-based functional assays were also conducted to test the fitness of cells after knock-in of the p.Arg658∗, p.Gln1701∗ and p.Gly1906Alafs∗12 PTVs and the sensitivity of different FANCM regions to genome editing.</div><div>Our results suggest that the N-terminal FANCM region upstream of p.Tyr725 harbors essential functions, whereas downstream regions appear dispensable. This is supported by our genetic data which indicate that all <em>FANCM</em> PTVs, excluding the two C-terminal p.Gln1701∗ and p.Gly1906Alafs∗12, are associated with an increased risk of ER-neg (OR = 1.41, <em>P</em> = 0.023) and TN (OR = 1.64, <em>P</em> = 0.0023). Notably, PTVs upstream of AA position 670 are associated with a moderate risk of developing TN breast cancer, and that even when the p.Arg658∗ carriers were excluded from the analysis. Importantly, our results confirm previous data indicating that p.Arg658∗ carriers are at moderate risk of developing ER-neg (OR = 2.08, P = 0.030) and TN (OR = 3.26; P = 0.0034), whereas carriers of p.Gln1701∗ and p.Gly1906Alafs∗12 should not be considered at increased risk. Our data are useful for counseling carriers of <em>FANCM</em> PTVs, but further analyses are warranted to obtain more precise risk estimates.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104619"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145486042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines","authors":"Eline E.F. Verreck ,&nbsp;Emily L. Postma ,&nbsp;Tanja Oostergo ,&nbsp;Joyce Meijer ,&nbsp;Anouk Eijkelboom ,&nbsp;Sabine Siesling ,&nbsp;Dimitris Rizopoulos ,&nbsp;Thijs van Dalen ,&nbsp;José H. Volders","doi":"10.1016/j.breast.2025.104664","DOIUrl":"10.1016/j.breast.2025.104664","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant systemic therapy has improved breast cancer outcomes over the past decades. Following the distinction of molecular subtypes and the introduction of gene expression profiling and prognostic tools, chemotherapy is less frequently recommended for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. However, recommendations for endocrine therapy (ET) remained unchanged. This study examines ET trends among HR+/HER2- patients in the Netherlands and factors influencing these trends.</div></div><div><h3>Methods</h3><div>All HR+/HER2- patients diagnosed between 2012 and 2022 who underwent surgery were selected from the Netherlands Cancer Registry. Patients were categorized by ET guideline indications: no indication; indication based on pathological, postoperative TNM-stage/grade; or indication based on clinical TNM-stage/grading on biopsy warranting neoadjuvant chemotherapy (NAC). The ET benefit was estimated for all patients using the PREDICT 2.0 tool. Logistic regression was used to identify factors associated with ET initiation.</div></div><div><h3>Results</h3><div>The study included 127,610 HR+/HER2- patients. The proportion starting ET according to guideline recommendations decreased from 91.2 % (2012) to 79.3 % (2022), with those who did not initiate ET having a lower PREDICT-estimated benefit (1.0 %) compared to those who did (1.5 %). Reduced ET initiation was associated with age 30–39, age &gt;80, and treatment in academic hospitals. In 2022, ET initiation varied by up to 19 percentage points across regions, while the PREDICT-estimated benefit showed no clinically relevant difference (ranging from 1.3 % to 1.5 %).</div></div><div><h3>Conclusion</h3><div>Despite unchanged guideline recommendations, fewer patients started ET over time. This trend, and regional variation, suggests that a more reticent approach by physicians to initiating ET for HR+/HER2- breast cancer may be contributing to it.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104664"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145666945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20–40 years","authors":"Ernest Diab ,&nbsp;Cyril Roussel-Simonin ,&nbsp;Federica Giugliano ,&nbsp;Julia Dixon-Douglas ,&nbsp;Alessandra Spata ,&nbsp;Martina Pagliuca ,&nbsp;Lauriane Minot ,&nbsp;Alexandre Xu-Vuillard ,&nbsp;Fernanda Mosele ,&nbsp;Thomas Grinda ,&nbsp;Alessandro Viansone ,&nbsp;Chayma Bousrih ,&nbsp;Jean Zeghondy ,&nbsp;Tarek Ben Ahmed ,&nbsp;Claudio Nicotra ,&nbsp;Arnaud Bayle ,&nbsp;Antoine Italiano ,&nbsp;Suzette Delaloge ,&nbsp;Barbara Pistilli ,&nbsp;Fabrice André ,&nbsp;Elie Rassy","doi":"10.1016/j.breast.2025.104690","DOIUrl":"10.1016/j.breast.2025.104690","url":null,"abstract":"<div><h3>Introduction</h3><div>Breast cancer in young adults (YA) aged 20–40 years has distinct clinical and biological traits compared with older patients. This study evaluated the genomic landscape of metastatic breast cancers (MBC) among YA.</div></div><div><h3>Methods</h3><div>Patients with MBC enrolled in the STING molecular profile platform (NCT04932525) between 2021 and May 2023 were included. Clinical and genomic features were analyzed by age (≤40 vs &gt; 40 years). Tumor profiling used the FoundationOne Liquid CDx assay (324 genes) at baseline or later in the disease course. Variant frequencies were compared across age groups.</div></div><div><h3>Results</h3><div>Of 432 eligible patients, 68 (16 %) were YA. Among 37 YA with hormone receptor positive (HR+) BC, frequent alterations included <em>TP53</em> (39 %), <em>ESR1</em> (27 %), <em>PIK3CA</em> (25 %), <em>FGFR3</em> (18 %), <em>FGFR4</em> (18 %), <em>FGFR19</em> (18 %), <em>CCND1</em> (18 %). Compared with older patients, YA with HR + tumors had fewer <em>RB1</em> (7 % vs 8 %; <em>p</em> = 0.03) and <em>PIK3CA</em> (25 % vs 31 %; <em>p</em> = 0.03) alterations. Among 28 YA with triple negative BC, the most common alterations were <em>TP53</em> (100 %), <em>PTEN</em> (26 %), <em>BRCA1</em> (22 %), <em>RB1</em> (17 %). <em>PTEN</em> mutations were more frequent among YA with TNBC than older patients (26 % vs 8 %; <em>p</em> = 0.009). Tiers I-III genomic alterations according to the ESMO scale of clinical actionability (ESCAT) were identified in 54 YA (79 %), including 48 tiers I-II alterations comprising <em>ESR1</em> (n = 12), <em>gBRCA1/2</em> (n = 11), <em>PIK3CA</em> (n = 13).</div></div><div><h3>Conclusions</h3><div>ESCAT tiers I-III alterations were reported in 79 % YA with MBC which supports the role of molecular profiling in YA. The differences detected in the genomic profiles of YA with BC and older patients may allude to potential different underlying disease biology.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104690"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-stratified toxicity patterns of CDK4/6 inhibitors in older women with breast cancer: Disproportionality analysis from the FAERS database","authors":"Bahadır Köylü ,&nbsp;Buğra Han Esen ,&nbsp;Cevat İlteriş Kıkılı ,&nbsp;Fatih Kemik ,&nbsp;Nazan Demir ,&nbsp;Şeyda Gündüz ,&nbsp;Şahin Laçin ,&nbsp;Deniz Tural ,&nbsp;Didem Tunalı ,&nbsp;Gülistan Bahat ,&nbsp;Fatih Selçukbiricik","doi":"10.1016/j.breast.2025.104687","DOIUrl":"10.1016/j.breast.2025.104687","url":null,"abstract":"<div><h3>Background</h3><div>Despite their benefits, the safety of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors in older patients remains underexplored. We aimed to investigate the toxicities associated with CDK4/6 inhibitors in subgroups of older patients, through analysis of the FAERS database.</div></div><div><h3>Methods</h3><div>In this retrospective pharmacovigilance analysis, we identified 49,223 females with breast cancer (aged 18–100 years), in which a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) was recorded as the primary suspect drug. Patients were stratified into four age groups: &lt;65, 65–74, 75–84, and ≥85 years. Disproportionality analysis using the reporting odds ratio method was conducted to detect positive disproportionality signals between individual adverse events and CDK4/6 inhibitors. We performed age-stratified multivariate analyses to detect age-related differences.</div></div><div><h3>Results</h3><div>Acute renal failure and interstitial lung disease associated with abemaciclib were reported more frequently in geriatric age subgroups, while gastrointestinal and hematologic adverse events showed a declining reporting frequency with advancing age. Significant age-related increases in the odds of reporting dementia, hearing and vestibular disorders, lens disorders, arthritis, thrombotic events, and central nervous system hemorrhagic complications were identified in palbociclib-treated patients. Ribociclib showed increased reporting of acute renal failure, chronic kidney disease, cardiac arrhythmias, and ischemic heart disease in geriatric age subgroups, whereas the reporting frequency of liver-related adverse events declined with advancing age.</div></div><div><h3>Conclusions</h3><div>Older adults receiving CDK4/6 inhibitors experience higher rates of renal, pulmonary, cardiac, and neurocognitive toxicities, with abemaciclib linked to renal and pulmonary, palbociclib to neurological and thrombotic/hemorrhagic, and ribociclib to renal and cardiac adverse events.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104687"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study","authors":"Nadia Bianco ,&nbsp;Carmine Valenza ,&nbsp;Monica Milano ,&nbsp;Roberta Multinu ,&nbsp;Elena Battaiotto ,&nbsp;Matteo Cavallone ,&nbsp;Giulia Malvezzi ,&nbsp;Dario Trapani ,&nbsp;Paolo Della Vigna ,&nbsp;Guido Bonomo ,&nbsp;Gianluca M. Varano ,&nbsp;Daniele Maiettini ,&nbsp;Maria Giovanna Pitoni ,&nbsp;Claudia Sangalli ,&nbsp;Elisabetta Munzone ,&nbsp;Giuseppe Curigliano ,&nbsp;Marco A. Colleoni ,&nbsp;Franco Orsi","doi":"10.1016/j.breast.2025.104667","DOIUrl":"10.1016/j.breast.2025.104667","url":null,"abstract":"<div><h3>Background</h3><div>Patients with visceral oligoprogressive and oligopersistent metastatic breast cancer (mBC) may benefit from metastasis-directed thermal ablation (TA) to all sites of metastasis, while maintaining the same systemic treatment, in order to delay the time to treatment failure (TTF). This study aims to assess the outcomes provided by this multimodal strategy.</div></div><div><h3>Methods</h3><div>We conducted a single-center, cohort study including consecutive patients with visceral oligoprogressive and oligopersistent mBC as per ESTRO/EORTC criteria, who underwent TA to all sites. Oligoprogression was defined as progressive disease in ≤5 metastatic sites with at least one other metastatic site maintaining the disease control; oligopersistence as ≤5 persistent lesions after systemic therapy. The main endpoint was post-TA progression-free survival (pTA-PFS).</div></div><div><h3>Results</h3><div>43 patients with oligoprogressive (cohort A) and 43 with oligopersistent (cohort B) disease were included; 4 (5 %) reported a TA-related adverse event. Overall, 122 visceral lesions were treated. In cohort A, median PFS before oligoprogression was 14.9 months (95 % CI, 9.7–20.1). After TA, 32 patients continued the same systemic treatment and 11 switched therapy; pTA-PFS was 9.1 months (95 % CI, 4.8–13.4), unchanged after excluding patients who switched systemic therapy. In cohort B, median PFS before oligopersistence was 7.8 months (95 % CI, 7.4–8.3). After TA, 35 patients continued the same systemic treatment, while 8 de-intensified to maintenance therapy; pTA-PFS was 16.7 months (95 % CI, 11.1–22.2).</div></div><div><h3>Conclusion</h3><div>Selected patients with visceral oligoprogressive and oligopersistent mBC appear to benefit from TA and systemic treatment continuation or modulation. This strategy can be implemented for selected patients in the framework of a multidisciplinary tumor board's shared decision.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104667"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of intra-operative injection of [99mTc] labelled colloidal nanoparticles for sentinel lymph nodes identification in breast cancer","authors":"Or Barkai ,&nbsp;Itamar Ashkenazi ,&nbsp;Aviad Hoffman","doi":"10.1016/j.breast.2026.104695","DOIUrl":"10.1016/j.breast.2026.104695","url":null,"abstract":"<div><h3>Background</h3><div>Sentinel lymph node (SLN) biopsy is a critical component of axillary staging in breast cancer management. Traditionally, Technetium-99m (Tc-99m) labelled colloidal nanoparticles is injected preoperatively in the nuclear medicine suite, followed by imaging, while blue dye is injected intraoperatively. Despite the use of topical anesthetics, preoperative radio-tracer injections can be painful, time-intensive, and resource-demanding. To address these limitations, we implemented intraoperative radio-tracer injection under anesthesia, instead of the traditional procedure at the nuclear imaging suite. This study evaluates whether intraoperative Tc-99m labelled colloidal nanoparticles administration affects SLN identification rates.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis of breast cancer patients who underwent surgery at Rambam Health Care Campus (2020–2023). Unfiltered Tc-99m sulphur colloid and blue dye were injected intraoperatively, and SLN detection rates were assessed.</div></div><div><h3>Results</h3><div>Among 350 patients (352 procedures), radioactive SLNs were successfully identified using Tc-99m in 89.5 % of cases. When both Tc-99m labelled colloidal nanoparticles and blue dye were used, the identification rate increased to 93.2 %. SLN detection was higher in upfront surgery compared to neoadjuvant therapy cases (radio-tracer alone: 92.2 % vs. 85.1 %, p = 0.048; dual tracer: 95.9 % vs. 88.8 %, p = 0.015). Advanced T-stage (OR 5.1, 95 %CI 2.3, 11.3; p &lt; 0.001) and N-stage (OR 3.7, 95 %CI 1.8, 7.3; p &lt; 0.001) were associated with lower SLN detection rates.</div></div><div><h3>Conclusions</h3><div>Intraoperative Tc-99m labelled colloidal nanoparticles injection is an effective alternative to preoperative injection, achieving comparable SLN detection rates while eliminating patient discomfort, reducing procedural complexity, and optimizing surgical workflow.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104695"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast composition and dose deposition to fat and fibroglandular tissues are associated with breast side effects after radiation therapy","authors":"Tanwiwat Jaikuna ,&nbsp;Fiona Wilson ,&nbsp;Carmel Anandadas ,&nbsp;David Azria ,&nbsp;Jenny Chang-Claude ,&nbsp;Maria Carmen De Santis ,&nbsp;Sara Gutiérrez-Enríquez ,&nbsp;Marcel van Herk ,&nbsp;Peter Hoskin ,&nbsp;Lea Kotzki ,&nbsp;Maarten Lambrecht ,&nbsp;Zoe Lingard ,&nbsp;Petra Seibold ,&nbsp;Alejandro Seoane ,&nbsp;Elena Sperk ,&nbsp;R Paul Symonds ,&nbsp;Christopher J. Talbot ,&nbsp;Tiziana Rancati ,&nbsp;Tim Rattay ,&nbsp;Victoria Reyes ,&nbsp;Marianne C. Aznar","doi":"10.1016/j.breast.2026.104694","DOIUrl":"10.1016/j.breast.2026.104694","url":null,"abstract":"<div><h3>Objective</h3><div>Breast comprises different tissues with potentially different dose responses to radiation therapy (RT). This study investigates the correlation between RT dose, breast composition, and side effects from breast RT.</div></div><div><h3>Material/methods</h3><div>Data from 922 early-stage breast cancer patients who underwent breast-conserving surgery and RT from the REQUITE study were included. Breast pain, oedema, atrophy, and induration were assessed immediately post-RT, one-year, and two-years post-RT. Maximum severity scores for each toxicity were used for analysis. Breast tissue was divided into “<em>fat</em>” and “<em>fibroglandular</em>” substructures from computed tomography (CT) using a Gaussian Mixture Model. The correlation between breast characteristics, toxicity, dosimetric parameters, and patient and clinical variables was investigated using ordinal regression. The model's fit was evaluated using the Akaike Information Criterion in SPSS v.29.</div></div><div><h3>Results</h3><div>Breast volume and breast density were associated with increased risk of breast oedema, atrophy, and induration in multivariable analysis (<em>p&lt;</em>0.05). Higher mean dose and dose uniformity were observed for fibroglandular compared to fatty tissue at all severity levels, while there was no significant difference in the maximum dose to either substructure. Higher dose deposit to fat was associated with breast pain and oedema, while breast atrophy and induration were associated with dose to fibroglandular tissue. All best-performing toxicity models included dosimetric parameters derived from breast composition.</div></div><div><h3>Conclusion</h3><div>Breast characterisation offers new insight into the link between dose and toxicity. Breast density and dose parameters from different substructures were associated with different breast toxicity. These findings further support the importance of dose homogeneity of breast RT planning.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104694"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of treatment response to neoadjuvant chemotherapy on brain metastasis patterns and breast cancer prognosis","authors":"Jihwan Yoo ,&nbsp;Yoon Jin Cha ,&nbsp;Sung Gwe Ahn ,&nbsp;Joon Jeong ,&nbsp;Hun Ho Park ,&nbsp;Sung Jun Ahn ,&nbsp;Bio Joo ,&nbsp;Ji Hyun Park ,&nbsp;Jee Hung Kim ,&nbsp;Soong June Bae","doi":"10.1016/j.breast.2025.104650","DOIUrl":"10.1016/j.breast.2025.104650","url":null,"abstract":"<div><h3>Background</h3><div>Brain metastases (BM) are a major cause of mortality in breast cancer. While pathologic complete response (pCR) after neoadjuvant chemotherapy is associated with favorable survival outcomes, its impact on BM development and prognosis remains unclear.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 1,244 patients with early-stage breast cancer who underwent neoadjuvant chemotherapy followed by surgery. Clinicopathological features, BM incidence, and survival outcomes were assessed. Propensity score matching (PSM) was applied to adjust for baseline differences. Gene expression profiling was performed in BM samples from pCR and non-pCR patients.</div></div><div><h3>Results</h3><div>Of these, 437 (35.1 %) patients achieved pCR and 52 (4.2 %) developed BM. In TNBC, non-pCR patients had a significantly higher BM rate (9.2 % vs. 3.3 %, <em>P</em> = 0.026), whereas no differences were observed in other subtypes. Patients with BM who achieved pCR were more likely to present with single brain lesion (42.9 % vs. 10.5 %, <em>P</em> = 0.016), undergo craniotomy (71.4 % vs. 31.6 %, <em>P</em> = 0.010), and less frequently had extracranial metastases (28.6 % vs. 73.7 %, <em>P</em> = 0.003). Median overall survival after BM was longer in the pCR (42 vs. 4 months, <em>P</em> = 0.002), and this benefit remained significant after PSM (43 vs. 10 months, <em>P</em> = 0.033). Transcriptomic analysis identified distinct molecular profiles, with upregulation of RPL27A and CTLA4 in pCR BM and non-pCR BM.</div></div><div><h3>Conclusions</h3><div>pCR was associated with lower metastatic burden and improved survival following BM diagnosis. Molecular differences between pCR and non-pCR BM suggest distinct mechanisms of metastatic evolution, suggesting the need for tailored surveillance and preventive strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104650"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in local, regional and contralateral breast tumor recurrence within five years after diagnosis in the Netherlands: a population-based study including 121347 patients","authors":"J. Meijer ,&nbsp;H.J.G.D. van den Bongard ,&nbsp;L.B. Koppert ,&nbsp;C.W. Menke-van der Houven van Oordt ,&nbsp;L. de Munck ,&nbsp;T.J.A. van Nijnatten ,&nbsp;M.J.C. van der Sangen ,&nbsp;R.J. Schipper ,&nbsp;M.K. Schmidt ,&nbsp;M.L. Smidt ,&nbsp;W. Vreuls ,&nbsp;M.C. van Maaren ,&nbsp;S. Siesling","doi":"10.1016/j.breast.2025.104673","DOIUrl":"10.1016/j.breast.2025.104673","url":null,"abstract":"<div><h3>Background</h3><div>The objective was to provide an overview of trends in five-year local recurrence (LR), regional recurrence (RR) and contralateral breast cancer (CBC) rates in the Netherlands from 2003 to 2008 and 2012–2016.</div></div><div><h3>Methods</h3><div>Women ≥18 years diagnosed with primary early breast cancer between 2003-2008 and 2012–2016 in the Netherlands were included. LR was defined as invasive tumor on the same side as the primary breast cancer. RR was defined as regional lymph node metastasis. CBC was defined as second primary invasive breast tumor in the contralateral breast. Five-year LR, RR and CBC rates were calculated and stratified for age, stage, subtype, and grade.</div></div><div><h3>Results</h3><div>Of the 121347 included patients, 5618 were diagnosed with a LR, RR or CBC. Five-year LR, RR and CBC rates decreased from 3.3 %, 1.9 % and 2.2 % in 2003 to 1.5 %, 1.6 % and 1.5 % in 2016, respectively, with fluctuations over the years. Slight increases were observed in RR rates for stage II-III, HR-/HER2+ and HR-/HER2-.</div></div><div><h3>Conclusion</h3><div>(s). The observed overall decline in LR, RR and CBC rates could reflect more effective and personalized breast cancer treatment. Our results provide realistic insights in LR, RR and CBC rates and might contribute to further optimization of treatment and surveillance strategies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104673"},"PeriodicalIF":7.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}